Introduction
Bluebird bio (NASDAQ:BLUE) is one of the most exciting biotechnology firms in the space. Their goal is to genetically engineer patients' own cells to address the genetic basis of severe diseases.
They've achieved early clinical successes on carefully selected targets with an approach strongly grounded in theory. However if they can prove the concept of this approach and develop market leading expertise, they will be able to treat a far wider spectrum genetic disease than their current set of targets, including many with orphan status and no existing treatments.
The elegance of the approach - modifying and reinserting a patient's own cells - is quite likely the future of treatment for genetic disease, and perhaps cancer and other cellular diseases as well.

